About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in San Francisco | 112 Studies

Clinical Trials LymphomaSan Francisco

Lymphoma Clinical Trials in San Francisco

Find 112 clinical trials for lymphoma near San Francisco, California. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in San Francisco

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 1-20 of 112 trials

TerminatedStudy to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the…NCT03598608·Gilbert, Arizona and 24 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingMosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaThis is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R…NCT06006117·Anderlecht and 47 others

CompletedStudy of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaThis is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in…NCT02947347·Mobile, Alabama and 127 others

CompletedMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaThis phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or…NCT01231919·Birmingham, Alabama and 24 others

RecruitingA Study of NX-1607 in Adults With Advanced MalignanciesThis is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced…NCT05107674·Duarte, California and 16 others

Active not recruitingMALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasSingle-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients.NCT03697512·Yvoir and 35 others

RecruitingAnti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaThis study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface…NCT04545762·San Francisco, California

CompletedStudy of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaThe purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or…NCT00312845·Opelika, Alabama and 205 others

RecruitingGlofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaThis phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back…NCT06252675·Davis, California and 3 others

Active not recruitingValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including…NCT04703192·Duarte, California and 59 others

Active not recruitingSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with…NCT04663347·Birmingham, Alabama and 56 others

CompletedDiagnostic Study of Patients With Aggressive Non-Hodgkin's LymphomaRATIONALE: Determination of genetic markers for aggressive non-Hodgkin's lymphoma may help identify patients with this disease and help predict the outcome of treatment.NCT00003863·Anniston, Alabama and 68 others

RecruitingSoquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaA Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in…NCT06561048·Duarte, California and 36 others

RecruitingChemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaPatients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in…NCT03719105·Birmingham, Alabama and 5 others

UnknownRituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's LymphomaThe purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and…NCT00041730·La Jolla, California and 14 others

CompletedCPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersThis is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in…NCT03454451·Tucson, Arizona and 26 others

RecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLThis is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or…NCT06500273·Gilbert, Arizona and 85 others

CompletedBrain Health Together: A Live-Streaming Group-Based Digital ProgramThe purpose of this study is to develop and test a comprehensive Brain Health Together program for older adults living with cognitive decline.NCT05818423·San Francisco, California

CompletedRituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00075946·Scottsdale, Arizona and 482 others

CompletedPK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma PatientsThis is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat…NCT00948090·Birmingham, Alabama and 41 others

Page 1 of 6Next

Other Conditions in San Francisco

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia